Given the recent evidence of CD8+ T cell involvement in hypertension pathophysiology [6], we therefore tested the vaccine on AngII-induced hypertension with the expectation that modulation of CD8+ T cells would alter the hypertensive response to AngII. This evidence concerns the gene CD8A and hypertensive disorder.